Under the Transition Services Agreement, we are transitioning to Novo Nordisk certain agreements and relationships with third parties that manufacture, store, and distribute zaltenibart for use in pr…
The APLA with Novo Nordisk includes variable consideration in the form of milestone payments that are contingent upon the achievement of specified development, regulatory or commercialization events
Omeros Corporation Debt Obligations
Instrument
Description
Confidence
Evidence
OMER-DEBT
Debt stack $226.6M
90%
Market cache reports total debt of $226.6M.
OMER-DEBT-11515
Warrants outstanding: 200000
90%
xbrl warrant detail from xbrl 2023-04-12.
OMER-DEBT-11516
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
Omeros Corporation Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Omeros Corporation.
Omeros Corporation Ownership
Holder
Name
Confidence
Evidence
OMER-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 162 tracked holders.
Omeros Corporation Extended Supply Chain Network
No secondary connectionsNo correlated companies found through shared supply chain relationships.